AI Article Synopsis
- - Atherosclerosis is viewed as a chronic inflammation process that contributes to cardiovascular issues like ischemic coronary artery disease (CAD), with Toll-like receptor 4 (TLR4) being a key player in this process.
- - The text reviews advancements in understanding how TLR4 is activated and its role in linking CAD to other inflammatory diseases, emphasizing its significance in the progression of atherosclerosis.
- - It also highlights various drugs that target TLR4 signaling to reduce atherosclerosis, suggesting that TLR4 could be an important therapeutic target for treating CAD.
Article Abstract
Atherosclerosis has been widely considered as a chronic inflammation process, which triggers a wide range of cardiovascular diseases such as ischemic coronary artery disease (CAD). Toll-like receptor 4 (TLR4), a primary receptor of the innate immune system, plays a pivotal role in the initiation and progression of atherosclerosis. Here we summarize recent progress on understanding the activation and function of TLR4 signaling in the initiation and development of CAD, with the focus on the role of TLR4 as a link between CAD and other inflammatory diseases. Furthermore, we list a variety of drugs which exert anti-atherosclerosis effects via targeting TLR4 signaling. Finally, we discuss the promise of TLR4 signaling as a therapeutic target for CAD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.intimp.2014.08.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!